Advanced Medical Solutions Group (AMS)

Sector:

Health Care

Index:

FTSE AIM 50

216.50p
   
  • Change Today:
    -8.50p
  • 52 Week High: 239.00p
  • 52 Week Low: 176.60p
  • Currency: UK Pounds
  • Shares Issued: 219.38m
  • Volume: 686,045
  • Market Cap: £474.96m
  • RiskGrade: 156
  • Beta: 0.00

Advanced Medical Solutions reports sharp rise in first-half revenue

By Josh White

Date: Wednesday 17 Sep 2025

LONDON (ShareCast) - (Sharecast News) - Advanced Medical Solutions reported a sharp rise in first-half revenue on Wednesday as it said the integration of last year's Peters Surgical acquisition was progressing well, with trading in line with expectations and full-year guidance reiterated.
The AIM-traded tissue-healing specialist posted group revenue of £110.8m for the six months to 30 June, up 63% on the prior year, or 66% at constant currency, as its surgical unit nearly doubled sales to £87.9m, boosted by £34.3m from Peters.

Advanced woundcare revenue rose 17% to £22.9m, recovering from previous declines, while adjusted EBITDA increased 42% to £24.4m and adjusted pre-tax profit climbed 11% to £16.4m.

Reported pre-tax profit rose 49% to £8.5m.

AMS said the performance was underpinned by double-digit growth in its existing business excluding Peters, including 14% growth in US LiquiBand, 10% in Rest of World LiquiBand and 37% in biosurgical products, supported by enhanced manufacturing efficiencies and improved collagen yields following the Syntacoll integration.

The group said restructuring of its Woundcare operations was completed in the first quarter, with the refocused business now generating double-digit operating margins.

Net debt stood at £50.1m, down from £55.8m at the end of 2024, while operating cash flow more than doubled to £15.1m.

The board raised the interim dividend 10% to 0.85p per share. AMS said it expected to sustain strong growth across its enlarged surgical portfolio, with its US regulatory programmes for biosurgical and suture products on track to support medium-term expansion, and that it remained on course to cut leverage to around 1x EBITDA by year-end.

"We are pleased to report another period of strong revenue growth, driven by continued momentum across key products," said chief executive Chris Meredith.

"These results also highlight the strength and resilience of our increasingly diversified portfolio and global footprint, which help to mitigate the impact of order phasing and market specific fluctuations.

"Integration of last year's acquisitions remain on track ... and in specialty areas, such as cardiovascular, set to strengthen in the second half and beyond.

"We are also making solid progress toward upcoming US product launches.

"We believe these initiatives will significantly enhance our earnings growth potential over the medium to long-term."

At 1358 BST, shares in Advanced Medical Solutions Group were up 1.21% at 209.5p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AMS Market Data

Currency UK Pounds
Share Price 216.50p
Change Today -8.50p
% Change -3.78 %
52 Week High 239.00p
52 Week Low 176.60p
Volume 686,045
Shares Issued 219.38m
Market Cap £474.96m
Beta 0.00
RiskGrade 156

AMS Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
92.64% below the market average92.64% below the market average92.64% below the market average92.64% below the market average92.64% below the market average
27.27% above the sector average27.27% above the sector average27.27% above the sector average27.27% above the sector average27.27% above the sector average
Price Trend
42.22% below the market average42.22% below the market average42.22% below the market average42.22% below the market average42.22% below the market average
2.86% below the sector average2.86% below the sector average2.86% below the sector average2.86% below the sector average2.86% below the sector average
Income
84.64% below the market average84.64% below the market average84.64% below the market average84.64% below the market average84.64% below the market average
50% below the sector average50% below the sector average50% below the sector average50% below the sector average50% below the sector average
Growth
16.16% below the market average16.16% below the market average16.16% below the market average16.16% below the market average16.16% below the market average
94.29% below the sector average94.29% below the sector average94.29% below the sector average94.29% below the sector average94.29% below the sector average

What The Brokers Say

Strong Buy 4
Buy 3
Neutral 0
Sell 1
Strong Sell 0
Total 8
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AMS Dividends

  Latest Previous
  Interim Final
Ex-Div 25-Sep-25 19-Jun-25
Paid 24-Oct-25 17-Jul-25
Amount 0.85p 1.83p

Trades for 02-Oct-2025

Time Volume / Share Price
16:59 126,901 @ 221.60p
16:35 79 @ 216.50p
16:35 42,135 @ 216.50p
16:35 914 @ 216.50p
16:35 684 @ 216.50p

AMS Key Personnel

CEO A Christopher (Chris) Meredith
CFO Eddie Johnson

Top of Page